Alopecia Areata
Conditions
Brief summary
Alopecia areata (AA) is a disease characterized by hair cycle dysfunction and the presence of peribulbar and perifollicular mononuclear cell infiltrate.1 The majority of patients report the rapid onset of one or several well-defined, usually round, 1 to 4 cm areas of scalp hair loss. A common feature is the presence of exclamation-mark hairs that are broken and short hairs that taper proximally. Commonly used treatment modalities are steroids (intra-lesional, topical or systemic), contact immunotherapy, anthraline, minoxidil, calcineurine inhibitors, topical retinoids, systemic immune modulating agents, photo-chemotherapy, dermatography wigs and hypnotherapy etc Apremilast is a newer drug. It is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), this may be effective treatment for a variety of inflammatory skin disorders such as alopecia areata.
Detailed description
Due to its increasing prevalence and lack of local data on its long term management, the investigators designed current study On Efficacy of Oral Apremilast in Alopecia areata in-order to evaluate its effectiveness.
Interventions
DRUGApremilast 30mg
Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
Sponsors
Jinnah Postgraduate Medical Centre
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Either gender. * Age 20-70 years.
Exclusion criteria
* Patients with history of connective tissue disorder, vasculitis, seropositive and seronegative arthritis * Patients with history of psoriasis. * Patients excluded from the study will be patients having history of previous treatments with some systemic agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of Oral Apremilast in the treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi | It will be assessed upto 12 weeks | Efficacy of Oral Apremilast for 12 weeks in alopecia areata will be assessed by using SALT score ( Severity of Alopecia Tool). The SALT score is computed by measuring the percentage of hair loss in each of 4 areas of the scalp-vertex (40%), right profile (18%), left profile (18%), and posterior (24%)-and adding the total to achieve a composite score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean difference of Salt score before and after the treatment | it will be assessed upto 12 weeks | SALT score difference before and after the treatment will be measured |
Countries
Pakistan
Outcome results
None listed